Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8444375 | European Journal of Cancer | 2013 | 9 Pages |
Abstract
Data from this large randomised Phase III study show that KRAS codon 12/13 mutations have negative prognostic value in metastatic CRC patients receiving treatment with FOLFOX/XELOX, but KRAS mutation status is not predictive of treatment benefit with cediranib, using PFS or OS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
John C. Smith, Laura Brooks, Paulo M. Hoff, Gael McWalter, Simon Dearden, Shethah R. Morgan, David Wilson, Jane D. Robertson, Juliane M. Jürgensmeier,